Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Pathologic Complete Response 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Hemangiosarcoma 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 115Radiotherapy 83Paclitaxel 77Fluorouracil 61Carboplatin 41Drug Therapy 34pembrolizumab 33Irinotecan 33tislelizumab 27Docetaxel 26Oxaliplatin 23Neoadjuvant Therapy 23toripalimab 22sintilimab 19camrelizumab 19Radiation 19Esophagectomy 17Capecitabine 17130-nm albumin-bound paclitaxel 17Surgical Procedures, Operative 15Leucovorin 15Nivolumab 14Cetuximab 14TP protocol 12S 1 (combination) 12Radiotherapy, Intensity-Modulated 12Albumin-Bound Paclitaxel 12nimotuzumab 11apatinib 10anlotinib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Esophageal Squamous Cell Carcinoma × SGN-LIV1A × Clear all
NCT04032704 2025-03-10

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Seagen Inc.

Phase 2 Terminated
205 enrolled 54 charts
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡